The group's principle activity is to deliver DNA drugs and vaccines to treat and prevent debilitating or life threatening diseases. The group also provides research services to develop the TriGrid(TM) Delivery System (TDS) as the safest, most efficacious, cost effective and easy to use system available for clinical delivery of DNA drugs. The group operates from United States.
